A controversial new drug for Alzheimer’s

The FDA has approved a new Alzheimer’s drug for the first time in almost 20 years. The hope is it would treat the more than 6 million Americans living with Alzheimer’s disease. But the effectiveness of the drug is up for question. Plus, the Biden administration’s split stance on Puerto Ricans and benefits. And, the upside to online concerts. Guests: Jose Delgado, Washington correspondent of El Nuevo Dia and Axios' Bob Herman, and Erica Pandey. Credits: Axios Today is produced in partnership with Pushkin Industries. The team includes Niala Boodhoo, Sara Kehaulani Goo, Dan Bobkoff, Alexandra Botti, Nuria Marquez Martinez, Sabeena Singhani, and Alex Sugiura. Music is composed by Evan Viola. You can reach us at [email protected]. Go deeper: FDA approves Biogen's Alzheimer's drug despite lack of evidence The future of concerts is hybrid Learn more about your ad choices. Visit megaphone.fm/adchoices

Om Podcasten

Axios podcast host Niala Boodhoo digs deep with leaders you know — or need to know — in business, politics and culture. Every week, all in under 20 minutes. About Axios: Axios is a digital media company launched in 2017. Axios helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app.  About Niala Boodhoo: Niala Boodhoo is the host of 1 big thing and previously hosted Axios Today She was the founding Host and Executive Producer of the award-winning news program The 21st. An alum of Reuters, The Miami Herald and WBEZ/Chicago, Niala was a 2019-2020 Knight-Wallace fellow.